UK Markets open in 9 mins.

Oxford BioMedica PLC (OXB.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
8.60-0.26 (-2.93%)
At close: 4:35PM BST
Full screen
Previous close8.86
Open8.45
Bid5.32 x 2513500
Ask10.00 x 11600000
Day's range8.45 - 9.00
52-week range2.98 - 11.50
Volume3,963,206
Avg. volume10,844,372
Market cap265.25M
Beta-1.29
PE ratio (TTM)-14.33
EPS (TTM)N/A
Earnings dateN/A
Dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Reuters21 days ago

    Oxford BioMedica wins big contract for Novartis cell therapy

    Novartis has signed a major contract with Oxford BioMedica that could earn the British company more than $100 million over three years for supplying the Swiss drugmaker with material for its novel cell therapy CTL019. The deal, announced by Oxford BioMedica on Thursday, could help put the veteran biotech firm on a path to sustainable profitability. The contract is for the supply of lentiviral vectors used to generate CTL019, a new kind of treatment for hard-to-treat leukaemia that is expected to reach the market this year.

  • Reuters - UK Focus21 days ago

    Oxford BioMedica wins big contract for Novartis cell therapy

    Novartis (IOB: 0QLR.IL - news) has signed a major contract with Oxford BioMedica (LSE: OXB.L - news) that could earn the British company more than $100 million over three years for supplying the Swiss drugmaker with material for its novel cell therapy CTL019. The deal, announced by Oxford BioMedica on Thursday, could help put the veteran biotech firm on a path to sustainable profitability. The contract is for the supply of lentiviral vectors used to generate CTL019, a new kind of treatment for hard-to-treat leukaemia that is expected to reach the market this year.

  • Reuters - UK Focus4 months ago

    Novartis wins speedy U.S. review of new leukaemia drug

    A new leukaemia treatment from Novartis (IOB: 0QLR.IL - news) for children and young adults will get priority review from the U.S. Food and Drug Administration (FDA), putting the Swiss drugmaker ahead of rivals working on similar cancer therapies. The FDA's announcement late Wednesday means the regulator plans to take action within six months on Novartis's so-called chimeric antigen receptor T cell therapy, or CAR (HKSE: 0699-OL.HK - news) -T, in partnership with University of Pennsylvania researchers.